Publications

CTD2 scientists at UCSF showed that tumor progression and dissemination are governed by evolutionary selection pressures that operate at a multicellular level and differ from the clonal events that drive initiation and the benign-malignant transition.

Integration of genome-scale RNAi and CRISPR-Cas9 screens across cancer cell lines with large protein-protein interaction networks revealed novel protein complexes.

Scientists established a panel of patient-derived xenografts (PDXs) from subtypes of T-cell lymphomas (TCL) and cell lines for target validation and drug testing. Stapled peptide ALRN-6924 which blocks interactions between p53, MDM2 and MDMX showed pre-clinical activity against TCL lines and PDXs.

Researchers performed an integrated analysis of TCGA genomic data and CPTAC proteomic data and demonstrated that A-to-I RNA editing contributes to proteomic diversity in breast cancer.

CTD² scientists at Fred Hutchinson showed that the triplet combination of WEE1 tyrosine kinase inhibitor AZD1775, cisplatin, and docetaxel is safe and tolerable in a phase I clinical trial of head and neck cancer.

CTD² scientists at UTSW employed a chemistry-first approach to map the associations between chemicals and genetic lesions in lung cancer. These chemical vulnerabilities may reveal novel druggable targets for lung cancer.